Press Release: TILT Biotherapeutics : TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint Resistant Metastatic Melanoma Phase I Trial at ESMO Immuno-Oncology 2023
HELSINKI, Finland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company at the forefront of developing cancer immunotherapies, presented safety and efficacy data from its international Phase I trial in...
Read full article »
TILT Biotherapeutics is a Finland-based clinical-stage biotechnology company that develops oncolytic immunotherapies for the treatment of cancer.
Read more